Back to Search
TRUMAN LANDOWSKI, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1922740091Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
PMID 15867381·Cancer Res·2005
8-other
Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.
PMID 18607542·Invest New Drugs·2009
8-other
Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma.
PMID 18319333·Mol Cancer Ther·2008
8-other
Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).
PMID 18062937·Biochem Pharmacol·2008
8-other
The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response.
PMID 17545547·Clin Cancer Res·2007
8-other
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
PMID 17351106·J Pharmacol Exp Ther·2007
7-preclinical
Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
PMID 17333195·Cancer Chemother Pharmacol·2007
8-other
Correlates of imexon sensitivity in human multiple myeloma cell lines.
PMID 16321833·Leuk Lymphoma·2006
8-other
Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.
PMID 16227632·Int J Gastrointest Cancer·2005
8-other
Targeting the bone marrow microenvironment in hematologic malignancies.
PMID 15190509·Semin Hematol·2004
6-review
Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.
PMID 14576847·Oncogene·2003
6-review
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
PMID 12764386·Leukemia·2003
8-other
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells.
PMID 12717418·Oncogene·2003
8-other
The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
PMID 12592346·Leukemia·2003
8-other
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
PMID 12483533·Oncogene·2002
8-other
Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells.
PMID 12439337·Anticancer Drugs·2002
8-other
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
PMID 12384435·Blood·2002
8-other
Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines.
PMID 11859150·J Immunol·2002
8-other
Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.
PMID 11751528·Clin Cancer Res·2001
8-other
Multiple Myeloma: New Insights and Therapeutic Approaches.
PMID 11701540·Hematology Am Soc Hematol Educ Program·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 42ND AND EMILE
OMAHA, NE 68198 - Phone
- (402) 559-4000
Quick Facts
- NPI
- 1922740091
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile